Supplementary Table 2. Time course of laboratory values.
| Variable | Group | Weeks |
|||||
|---|---|---|---|---|---|---|---|
| 0 | 4 | 8 | 12 | 24 | 52 | ||
| Red blood cell count, 104/µL | Combination | 475 ± 49 (94) | 465 ± 50* (73) | 455 ± 54* (61) | 456 ± 56* (65) | 453 ± 50* (69) | 452 ± 55* (68) |
| Fenofibrate | 471 ± 42 (39) | 463 ± 45* (37) | 456 ± 42* (35) | 453 ± 48* (34) | 456 ± 42* (35) | 450 ± 45* (34) | |
| Ezetimibe | 479 ± 49 (39) | 476 ± 49 (36) | 478 ± 49 (33) | 467 ± 46 (36) | 473 ± 45 (37) | 475 ± 43*§ (36) | |
| Hemoglobin, g/dL | Combination | 14.5 ± 1.5 (95) | 14.2 ± 1.5* (74) | 13.8 ± 1.6* (62) | 13.9 ± 1.7* (66) | 13.8 ± 1.4* (70) | 13.7 ± 1.7* (68) |
| Fenofibrate | 14.6 ± 1.3 (40) | 14.3 ± 1.3* (38) | 14.2 ± 1.3* (36) | 14.1 ± 1.4* (35) | 14.2 ± 1.3 (36) | 14.0 ± 1.3* (34) | |
| Ezetimibe | 14.8 ± 1.7 (39) | 14.7 ± 1.7 (36) | 14.7 ± 1.6§ (33) | 14.4 ± 1.6 (36) | 14.7 ± 1.6§ (37) | 14.7 ± 1.4§ (36) | |
| CPK, IU/L | Combination | 127 ± 96 (96) | 127 ± 63 (78) | 142 ± 95* (65) | 179 ± 189* (69) | 143 ± 96* (70) | 138 ± 86* (70) |
| Fenofibrate | 140 ± 94 (41) | 165 ± 186 (40) | 159 ± 125 (37) | 174 ± 145 (34) | 143 ± 105 (34) | 147 ± 88 (33) | |
| Ezetimibe | 120 ± 54 (42) | 150 ± 152 (39) | 123 ± 48 (35) | 124 ± 56 (39) | 117 ± 47 (39) | 126 ± 45 (33) | |
| AST (GOT), IU/L | Combination | 27 ± 12 (100) | 34 ± 38 (83) | 32 ± 16 (69) | 33 ± 18* (70) | 29 ± 16 (72) | 30 ± 18 (70) |
| Fenofibrate | 24 ± 10 (44) | 26 ± 12* (42) | 34 ± 32* (38) | 32 ± 21* (36) | 25 ± 10 (37) | 23 ± 7§ (35) | |
| Ezetimibe | 27 ± 12 (44) | 26 ± 9 (40) | 26 ± 11 (36) | 28 ± 12 (39) | 28 ± 13 (39) | 27 ± 9 (35) | |
| ALT (GPT), IU/L | Combination | 34 ± 23 (100) | 35 ± 30 (83) | 35 ± 24 (69) | 35 ± 25 (70) | 28 ± 17* (72) | 28 ± 23* (70) |
| Fenofibrate | 29 ± 16 (44) | 32 ± 25 (42) | 35 ± 29 (38) | 36 ± 23 (36) | 25 ± 14 (37) | 24 ± 14* (35) | |
| Ezetimibe | 30 ± 18 (44) | 30 ± 18 (40) | 29 ± 22 (36) | 31 ± 18 (39) | 31 ± 18 (39) | 30 ± 13 (34) | |
| Uric acid, mg/dL | Combination | 5.9 ± 1.5 (100) | 4.6 ± 1.2* (80) | 4.5 ± 1.2* (66) | 4.6 ± 1.2* (70) | 4.6 ± 1.3* (72) | 4.7 ± 1.3* (70) |
| Fenofibrate | 6.0 ± 1.4 (44) | 4.9 ± 1.5* (42) | 4.8 ± 1.2* (38) | 5.0 ± 1.6* (36) | 5.2 ± 1.6* (37) | 5.2 ± 1.5* (35) | |
| Ezetimibe | 6.0 ± 1.4 (43) | 6.0 ± 1.4§ (40) | 5.8 ± 1.4§ (36) | 5.8 ± 1.5*§ (39) | 6.0 ± 1.3§ (39) | 5.9 ± 1.5§ (35) | |
| Creatinine, mg/dL | Combination | 0.74 ± 0.16 (100) | 0.85 ± 0.18* (80) | 0.87 ± 0.23* (66) | 0.84 ± 0.18* (70) | 0.85 ± 0.29* (72) | 0.84 ± 0.21* (70) |
| Fenofibrate | 0.77 ± 0.20 (44) | 0.85 ± 0.20* (42) | 0.88 ± 0.21* (38) | 0.86 ± 0.20* (36) | 0.87 ± 0.16* (37) | 0.88 ± 0.21* (35) | |
| Ezetimibe | 0.81 ± 0.22 (43) | 0.83 ± 0.24 (40) | 0.82 ± 0.25 (36) | 0.81 ± 0.27§ (39) | 0.80 ± 0.21 (39) | 0.79 ± 0.23 (35) | |
Values are means ± SD and numbers of patients (in parentheses)
*
p < 0.05 (vs Baseline), one-sample Wilcoxon test;
§
p < 0.05 (vs Combination value for the same week), two-sided for between-group comparison by Wilcoxon test.
CPK, creatine phosphokinase; AST (GOT), aspartate aminotransferase; ALT (GPT), alanine aminotransferase